KRAS and lung cancer: We have previously demonstrated that inhibition of PP2A, through mutation or siRNA-mediated knockdown of PP2A-Aα, contributes to MEK1/2 inhibitor resistance in KRAS-mutant colon and lung cancers (23, 28).